• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.

作者信息

Roos R A, Tijssen M A, van der Velde E A, Breimer D D

机构信息

Department of Neurology, Academic Hospital, Leiden, The Netherlands.

出版信息

Clin Neurol Neurosurg. 1993 Sep;95(3):215-9. doi: 10.1016/0303-8467(93)90126-2.

DOI:10.1016/0303-8467(93)90126-2
PMID:8242964
Abstract

We studied the influence of dietary protein intake on the plasma level profile of levodopa, carbidopa, and 3-O-methyldopa and clinical efficacy in 12 patients with idiopathic Parkinson's disease after intake of one levodopa-carbidopa 200/50 controlled release tablet (Sinemet CR; LC-CR). The tablet was given 1 h before the protein rich meal on one day (fasted) and together with the meal on an other day (non-fasted). Higher levodopa and carbidopa concentrations were reached when the LC-CR was taken 1 h before the meal, but the plasma level profile for levodopa was flatter in the non-fasted state. The area under the curve for levodopa was slightly higher in the fasted condition. For the clinical variables walking and tapping slightly better clinical results (P = 0.08) were found in the fasted condition with the higher levodopa levels. If the patient on levodopa is in a clinically satisfactory condition, then non-fasted condition could be preferred because of the smooth plasma level profile demonstrated. However, if the initial levodopa concentrations are not in the critical range to be effective for the patient, the advice should be to take the drug in a fasted condition.

摘要

相似文献

1
The influence of a standard meal on Sinemet CR absorption in patients with Parkinson's disease.
Clin Neurol Neurosurg. 1993 Sep;95(3):215-9. doi: 10.1016/0303-8467(93)90126-2.
2
Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.息宁控释片的药代动力学和生物利用度:人体研究综述
Neurology. 1989 Nov;39(11 Suppl 2):25-38.
3
Comparative multiple-dose pharmacokinetics of controlled-release levodopa products.左旋多巴控释制剂的比较多剂量药代动力学
Eur Neurol. 1992;32(6):343-8. doi: 10.1159/000116858.
4
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study.息宁与阿他美(通用名卡比多巴/左旋多巴)的药代动力学比较:一项单剂量研究。
Mov Disord. 1996 Jul;11(4):427-30. doi: 10.1002/mds.870110412.
5
Clinical efficacy of Sinemet CR 50/200 versus Sinemet 25/100 in patients with fluctuating Parkinson's disease. An open, and a double-blind, double-dummy, multicenter treatment evaluation. The Dutch Sinemet CR Study Group.息宁控释片50/200与息宁25/100治疗帕金森病症状波动患者的临床疗效:一项开放及双盲、双模拟、多中心治疗评估。荷兰息宁控释片研究组
Clin Neurol Neurosurg. 1992;94(3):205-11. doi: 10.1016/0303-8467(92)90090-p.
6
Controlled-release carbidopa/levodopa (Sinemet 50/200 CR4): clinical and pharmacokinetic studies.控释卡比多巴/左旋多巴(息宁50/200 CR4):临床和药代动力学研究。
Neurology. 1989 Nov;39(11 Suppl 2):45-53; discussion 59.
7
Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients.进餐时间对帕金森病患者左旋多巴/卡比多巴控释制剂[校正后]动力学-动态曲线的影响。
Eur J Clin Pharmacol. 1998 Jun;54(4):303-8. doi: 10.1007/s002280050464.
8
Plasma levels of levodopa and its main metabolites in parkinsonian patients after conventional and controlled-release levodopa-carbidopa associations.帕金森病患者在使用常规和控释左旋多巴-卡比多巴联合制剂后血浆中左旋多巴及其主要代谢产物的水平。
Eur Neurol. 1993;33(1):69-73. doi: 10.1159/000116905.
9
Controlled release levodopa/carbidopa 25/100 (Sinemet CR 25/100): pharmacokinetics and clinical efficacy in untreated parkinsonian patients.控释左旋多巴/卡比多巴25/100(息宁控释片25/100):未经治疗的帕金森病患者的药代动力学和临床疗效
Clin Neuropharmacol. 1994 Oct;17(5):429-34. doi: 10.1097/00002826-199410000-00005.
10
Controlled-release carbidopa/levodopa (CR) in parkinsonian patients with response fluctuations on standard levodopa treatment: clinical and pharmacokinetic observations.接受标准左旋多巴治疗出现反应波动的帕金森病患者使用控释卡比多巴/左旋多巴(CR):临床及药代动力学观察
Neurology. 1989 Nov;39(11 Suppl 2):88-92; discussion 95.

引用本文的文献

1
Model-based optimization of controlled release formulation of levodopa for Parkinson's disease.基于模型的帕金森病左旋多巴控释制剂的优化。
Sci Rep. 2023 Sep 22;13(1):15869. doi: 10.1038/s41598-023-42878-5.
2
How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.如何优化帕金森病治疗的效果和安全性?——药物与食物和膳食补充剂相互作用的系统评价。
Curr Neuropharmacol. 2022;20(7):1427-1447. doi: 10.2174/1570159X19666211116142806.
3
Protein-Restricted Diets for Ameliorating Motor Fluctuations in Parkinson's Disease.
蛋白质限制饮食改善帕金森病运动波动
Front Aging Neurosci. 2017 Jun 28;9:206. doi: 10.3389/fnagi.2017.00206. eCollection 2017.
4
Pharmacokinetics of Rytary, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.卡比多巴-左旋多巴控释胶囊(Rytary)的药代动力学研究。
Clin Pharmacokinet. 2017 Sep;56(9):999-1014. doi: 10.1007/s40262-017-0511-y.
5
Clinical Pharmacokinetics of IPX066: Evaluation of Dose Proportionality and Effect of Food in Healthy Volunteers.IPX066的临床药代动力学:健康志愿者中剂量比例性及食物影响的评估。
Clin Neuropharmacol. 2016 Jan-Feb;39(1):10-7. doi: 10.1097/WNF.0000000000000126.